Bladder cancer | Guidance and guideline topic | NICE

Everything NICE has produced on the topic of bladder cancer. Includes any related guidelines, NICE Pathways and quality standards.

3 new

and

0 updated

products since January 2017.

NICE Pathways - mapping our guidance

Quality standards

Bladder cancer (QS106) December 2015
Suspected cancer (QS124) June 2016

NICE Guidelines

Bladder cancer: diagnosis and management (NG2) February 2015
Improving outcomes in urological cancers (CSG2) September 2002
Suspected cancer: recognition and referral (NG12) June 2015

Interventional procedures guidance

Electrically-stimulated intravesical chemotherapy for superficial bladder cancer (IPG277) November 2008
Intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer (IPG235) October 2007
Laparoscopic cystectomy (IPG287) February 2009

Technology appraisal guidance

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272) January 2013

In development

Atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy [ID939] (GID-TA10111) TBC Technology appraisal guidance
Nivolumab for treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy [ID995] (GID-TA10163) February 2018 Technology appraisal guidance
Pembrolizumab for urothelial cancer [ID1019] (GID-TA10113) November 2017 Technology appraisal guidance